Structure via PubChem · Public domain (PubChem)
zafirlukast
Sign in to saveAlso known as Accolate®, ICI-204219, 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide, cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate, 4-(5-Cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-O-tolylsulfonylbenzamide, ICI-204,219, Cyclopentyl 3-(2-methoxy-4-((O-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
Zafirlukast is an orally administered leukotriene receptor antagonist (LTRA) used for the chronic treatment of asthma. While zafirlukast is generally well tolerated, headaches and stomach upset often occur. Some rare side effects can occur, which can be life-threatening, such as liver failure. Eosinophilic granulomatosis with polyangiitis has been associated with zafirlukast, but the relationship is not thought to be causative. Overdoses of zafirlukast tend to be self-limiting.
Chemical data
- Formula
- C31H33N3O6S
- Molecular weight
- 575.7 g/mol
- IUPAC name
- cyclopentyl N-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methylindol-5-yl]carbamate
- SMILES
- CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
- InChIKey
- YEEZWCHGZNKEEK-UHFFFAOYSA-N
- XLogP
- 5.5
- Polar surface area
- 124 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
680 papers- Zafirlukast.2006
- Zafirlukast.2012
- Zafirlukast.2026
- Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.Drugs · 1998
- Repurposing zafirlukast confers renal protection in ischemia-reperfusion injury via suppressing macrophage METosis.International immunopharmacology · 2025
via PubMed
~16 min read
Encyclopedic overview
40 sectionsContents
- Medical uses
- Available forms
- Specific populations
- Pediatrics
- Geriatrics
- Pregnancy
- Lactation
- Renal impairment
- Hepatic impairment
- Contraindications
- Adverse effects
- Neuropsychiatric effects
- Hepatotoxicity
- Eosinophilic granulomatosis with polyangiitis
- Interactions
- Drug–drug interactions
- Drug-food interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Pharmacogenomics
- LTC4 synthase
- CYP2C9
- Chemistry
- Synthesis
- Physiochemical properties
- History
- Society and culture
- Economics
- Brand names
- Research
- Mechanism of action
- Other indications
- Veterinary use
- References
- External links
{{Drugbox | Watchedfields = changed | verifiedrevid = 470635429 | IUPAC_name = Cyclopentyl 3-{2-methoxy-4-[(o-tolylsulfonyl)carbamoyl]benzyl}-1-methyl-1H-indol-5-ylcarbamate | image = Zafirlukast.svg | image_class = skin-invert-image | width = 275 | image2 = Zafirlukast 3D ball-and-stick.png | image_class2 = bg-transparent
| tradename = Accolate | Drugs.com = | MedlinePlus = a697007 | DailyMedID = Zafirlukast | pregnancy_AU = B1 | pregnancy_US = B |pregnancy_US_comment= | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = POM | legal_US = | legal_status = | routes_of_administration = Oral
Excerpted from Wikipedia’s “zafirlukast” article, available under the CC BY-SA 4.0 licence.